An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Trial Profile

An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Clostridium-difficile-infections
  • Focus Therapeutic Use
  • Acronyms PUNCH Open Label; PUNCH SOS
  • Sponsors Rebiotix
  • Most Recent Events

    • 24 Apr 2018 Results of a comparative analysis from PUNCH CD2 and PUNCH SOS trials presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
    • 24 Apr 2018 Results of a comparative analysis from PUNCH CD2 and PUNCH SOS trials presented in a Rebiotix Inc. media release.
    • 08 Oct 2017 Primary endpoint of absence of CDI at 8 weeks from the last dose has been met, according to results presented at the IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top